Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment

Richard Fleming, Lyndal Harborne, David T. MacLaughlin, Daniel Ling, Jane Norman, Naveed Sattar, David Seifer

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Assessment of ovarian responses to metformin treatment in obese women with polycystic ovary syndrome (PCOS). Prospective treatment with randomization to two doses of metformin. University teaching hospital. Obese women (n = 82) with PCOS. Markers of ovarian function were assessed after 4 and 8 months. Hormone (androgens and müllerian-inhibiting substance [MIS]) changes over time. There was no difference in the reproductive hormone changes between the doses of metformin, and data were combined for further analyses. Significant responses to treatment were recorded for menstrual frequency and androstenedione (A) (reduction) within the first 4 months of treatment. However, suppression of the elevated circulating MIS concentrations required protracted treatment, because no change was observed in the first 4 months--only in the second 4-month assessment period. Metformin treatment of PCOS leads to rapid suppression of A and improved menstrual frequency. Suppression of MIS is a delayed response that may be secondary to the development of a cohort of follicles that underwent initial recruitment in an environment of reduced insulin stimulation.

Original languageEnglish (US)
Pages (from-to)130-136
Number of pages7
JournalFertility and Sterility
Volume83
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Metformin
Serum
Therapeutics
Hormones
Androstenedione
Random Allocation
Teaching Hospitals
Androgens
Insulin

Keywords

  • metformin
  • Müllerian-inhibiting substance
  • ovarian follicles
  • PCOS

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. / Fleming, Richard; Harborne, Lyndal; MacLaughlin, David T.; Ling, Daniel; Norman, Jane; Sattar, Naveed; Seifer, David.

In: Fertility and Sterility, Vol. 83, No. 1, 01.2005, p. 130-136.

Research output: Contribution to journalArticle

Fleming, Richard ; Harborne, Lyndal ; MacLaughlin, David T. ; Ling, Daniel ; Norman, Jane ; Sattar, Naveed ; Seifer, David. / Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. In: Fertility and Sterility. 2005 ; Vol. 83, No. 1. pp. 130-136.
@article{da27ea2c58ca44caac0e27fb5d0ba653,
title = "Metformin reduces serum m{\"u}llerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment",
abstract = "Assessment of ovarian responses to metformin treatment in obese women with polycystic ovary syndrome (PCOS). Prospective treatment with randomization to two doses of metformin. University teaching hospital. Obese women (n = 82) with PCOS. Markers of ovarian function were assessed after 4 and 8 months. Hormone (androgens and m{\"u}llerian-inhibiting substance [MIS]) changes over time. There was no difference in the reproductive hormone changes between the doses of metformin, and data were combined for further analyses. Significant responses to treatment were recorded for menstrual frequency and androstenedione (A) (reduction) within the first 4 months of treatment. However, suppression of the elevated circulating MIS concentrations required protracted treatment, because no change was observed in the first 4 months--only in the second 4-month assessment period. Metformin treatment of PCOS leads to rapid suppression of A and improved menstrual frequency. Suppression of MIS is a delayed response that may be secondary to the development of a cohort of follicles that underwent initial recruitment in an environment of reduced insulin stimulation.",
keywords = "metformin, M{\"u}llerian-inhibiting substance, ovarian follicles, PCOS",
author = "Richard Fleming and Lyndal Harborne and MacLaughlin, {David T.} and Daniel Ling and Jane Norman and Naveed Sattar and David Seifer",
year = "2005",
month = "1",
doi = "10.1016/j.fertnstert.2004.05.098",
language = "English (US)",
volume = "83",
pages = "130--136",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment

AU - Fleming, Richard

AU - Harborne, Lyndal

AU - MacLaughlin, David T.

AU - Ling, Daniel

AU - Norman, Jane

AU - Sattar, Naveed

AU - Seifer, David

PY - 2005/1

Y1 - 2005/1

N2 - Assessment of ovarian responses to metformin treatment in obese women with polycystic ovary syndrome (PCOS). Prospective treatment with randomization to two doses of metformin. University teaching hospital. Obese women (n = 82) with PCOS. Markers of ovarian function were assessed after 4 and 8 months. Hormone (androgens and müllerian-inhibiting substance [MIS]) changes over time. There was no difference in the reproductive hormone changes between the doses of metformin, and data were combined for further analyses. Significant responses to treatment were recorded for menstrual frequency and androstenedione (A) (reduction) within the first 4 months of treatment. However, suppression of the elevated circulating MIS concentrations required protracted treatment, because no change was observed in the first 4 months--only in the second 4-month assessment period. Metformin treatment of PCOS leads to rapid suppression of A and improved menstrual frequency. Suppression of MIS is a delayed response that may be secondary to the development of a cohort of follicles that underwent initial recruitment in an environment of reduced insulin stimulation.

AB - Assessment of ovarian responses to metformin treatment in obese women with polycystic ovary syndrome (PCOS). Prospective treatment with randomization to two doses of metformin. University teaching hospital. Obese women (n = 82) with PCOS. Markers of ovarian function were assessed after 4 and 8 months. Hormone (androgens and müllerian-inhibiting substance [MIS]) changes over time. There was no difference in the reproductive hormone changes between the doses of metformin, and data were combined for further analyses. Significant responses to treatment were recorded for menstrual frequency and androstenedione (A) (reduction) within the first 4 months of treatment. However, suppression of the elevated circulating MIS concentrations required protracted treatment, because no change was observed in the first 4 months--only in the second 4-month assessment period. Metformin treatment of PCOS leads to rapid suppression of A and improved menstrual frequency. Suppression of MIS is a delayed response that may be secondary to the development of a cohort of follicles that underwent initial recruitment in an environment of reduced insulin stimulation.

KW - metformin

KW - Müllerian-inhibiting substance

KW - ovarian follicles

KW - PCOS

UR - http://www.scopus.com/inward/record.url?scp=11844295456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844295456&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2004.05.098

DO - 10.1016/j.fertnstert.2004.05.098

M3 - Article

C2 - 15652898

AN - SCOPUS:11844295456

VL - 83

SP - 130

EP - 136

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -